주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요

Elsevier
엘스비어와 함께 출판

Profile

Jun Wang

JW

Jun Wang

Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, USA

Jun Wang received his B.Sc in Chemistry from Wuhan University, China, in 2003. He worked one year as a research scientist at Scinopharm Biomedical Co. Ltd in Kunshan, Jiangsu province. In 2004, he joined Dr. Shaoqin Yao’s group in the Department of Chemistry, National University of Singapore as a graduate student. He gained experience in peptide chemistry and chemical biology by studying matrix metalloproteases using activity-based chemical probes and peptidomimetic inhibitors. After obtaining an MSc degree in chemistry in 2006, he joined Dr. William F. DeGrado’s group at the University of Pennsylvania. His Ph.D. project focused on the design of channel blockers targeting the drug-resistant influenza A virus M2 proton channel. After graduating in 2010 with a Ph.D. degree in chemistry, he continued the postdoctoral research in the DeGrado lab and relocated with the lab to UCSF in 2011. Dr. Wang started his independent academic career in 2014 as an Assistant Professor at the Department of Pharmacology and Toxicology at the University of Arizona. In 2020, he was promoted to Associate Professor with Tenure. In 2022, he joined the Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, and was promoted to professor in 2024. Dr. Wang received the ABRC Young Investigator Award in 2017, the College of Pharmacy A. Jay Gandolfi New Investigator Award in 2019, the CAPA distinguished faculty award in 2022, and the New Jersey Health Foundation Excellence in Research Award in 2023. Dr. Wang is the editorial board member of multiple journals, including Journal of Medicinal Chemistry, Medicinal Research Reviews, and Acta Pharmaceutica Sinica B. He is also a frequent ad hoc reviewer for multiple funding agencies. Dr. Wang’s research has been funded by grants from the National Institutes of Health, ABRC, and PhRMA Foundation.